← Back to Clinical Trials
Recruiting NCT06916221

NCT06916221 BID LTM Digital Intervention in Aging

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06916221
Status Recruiting
Phase
Sponsor University of California, San Francisco
Condition Long-Term Memory
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2025-08-20
Primary Completion 2028-01-31

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Long Term MemoryWorder

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2025-08-20 with a primary completion date of 2028-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Healthy aging is typically accompanied by diminished capability for learning and retrieval of high-fidelity long-term memory (LTM). The decline in these faculties is accelerated and becomes significant deficits in LTM and cognitive control functions at the level or a diagnosis of Mild Cognitive Impairment (MCI). Training with the navigation game, relative to training with control games, is expected to improve LTM performance for older adult participants. Researchers will compare two different digital interventions to assess whether they may be helpful in improving cognitive function. Participants will conduct study activities remotely (e.g., at-home): 1. Baseline Assessment. Complete a series of cognitive assessments and surveys. 2. Intervention. Engage in a digital intervention for up to 8 weeks. 3. Post Intervention Assessment. Complete the same cognitive assessments and surveys as the Baseline Assessment. 4. Follow-Up Assessment. Six months after the intervention ends, participants will complete the same cognitive assessments and surveys as the Baseline Assessment.

Eligibility Criteria

Inclusion Criteria: * Minimum of 12 years of education * English fluency: All task instructions are presented in English language text. In order to control for sufficient and equivalent participant comprehension of the procedures and instructions, we require their self-report of fluency in English. * Normal or corrected-to-normal vision * Normal or corrected-to-normal hearing * Medically healthy older adults, including those with below-average cognitive performance /MCI patients without dementia referred by neuropsychologists (i.e., no participant medical records will be reviewed). Exclusion Criteria: * Under the age of 60 * Clinical diagnosis of neurological or psychiatric disorder Clinical diagnosis of dementia or AD8 score of \>4 * Visually or hearing impaired without correction to normal * Regularly (one or more times per week) practicing an instrument within the last year * 10 years or more of formal musical instrument training

Contact & Investigator

Central Contact

Melissa Arioli, AB

✉ bid.core@ucsf.edu

📞 (415) 502-7321

Principal Investigator

Peter E Wais, PhD

PRINCIPAL INVESTIGATOR

University of California, San Francisco

Frequently Asked Questions

Who can join the NCT06916221 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, up to 85 Years, studying Long-Term Memory. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06916221 currently recruiting?

Yes, NCT06916221 is actively recruiting participants. Contact the research team at bid.core@ucsf.edu for enrollment information.

Where is the NCT06916221 trial being conducted?

This trial is being conducted at San Francisco, United States.

Who is sponsoring the NCT06916221 clinical trial?

NCT06916221 is sponsored by University of California, San Francisco. The principal investigator is Peter E Wais, PhD at University of California, San Francisco. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology